维奈克拉联合阿糖胞苷±伊达比星或阿扎胞苷治疗儿童及青少年复发/难治性急性髓系白血病(VENAML):多中心1期扩展研究
该多中心1期扩展研究纳入2-24岁复发/难治性AML患者,在推荐2期剂量下评估维奈克拉联合高剂量阿糖胞苷(±伊达比星或阿扎胞苷)的疗效与安全性。44例可评估患者中,1周期后57%(95%CI 41-72)达完全缓解(±血液学恢复),19例MRD阴性;常见3/4级不良事件为发热性中性粒细胞减少(52%)、胃肠道疾病(32%)和感染(25%)。结论认为该方案活性可接受、安全性可控。
要点
- 维奈克拉联合高剂量阿糖胞苷在儿童复发/难治AML中1周期完全缓解率57%。
- 44例中19例达MRD阴性,提示深度缓解。
- 常见3/4级不良事件为发热性中性粒细胞减少、胃肠道疾病和感染。
核心结论
- 维奈克拉联合高剂量阿糖胞苷在儿童复发/难治性AML中具有活性且安全性可接受。
研究设计与样本
- 多中心1期扩展研究,纳入2-24岁复发/难治AML患者,共44例在推荐2期剂量下治疗。
主要发现
- 1周期后25例(57%,95%CI 41-72)达完全缓解(±血液学恢复),其中19例MRD阴性。
- 常见3/4级不良事件:发热性中性粒细胞减少23例(52%)、胃肠道疾病14例(32%)包括结肠炎4例(9%)、感染11例(25%)。
- 发生2例5级不良事件,分别因脓毒症和多器官衰竭。
关键数值与推荐
- 推荐2期剂量下维奈克拉360 mg/m2(最大600 mg)每日口服,第1天减半,共27天。
- 阿糖胞苷1000 mg/m2每12小时静脉给药,第8-11天共8次。
- 队列B联合伊达比星12 mg/m2第8天;队列C联合阿扎胞苷75 mg/m2第1-7天。
临床怎么用
- 该方案可作为儿童复发/难治性AML的候选治疗选择,需监测发热性中性粒细胞减少和感染。
局限性
- 为1期扩展研究,样本量有限(44例),非随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The prognosis for paediatric patients with relapsed or refractory acute myeloid leukaemia remains poor. Although encouraging, published paediatric data on venetoclax combined with intensive chemotherapy are scarce. We aimed to refine efficacy and toxicity estimates from the previously published dose-escalation phase of this study. METHODS: This multicentre, phase 1 study included two phases, an initial dose-escalation phase to identify the primary endpoint of recommended phase 2 dose (RP2D; previously reported), followed by an expansion cohort phase, the results of which are reported here. Paediatric patients (aged 2-24 years) with relapsed or refractory acute myeloid leukaemia from three US research hospitals were included. Patients had at least 5% blasts in the bone marrow by morphology or at least 1% blasts by flow cytometry. Treatment varied across cohorts. Patients received oral venetoclax 360 mg/m2 (maximum 600 mg) daily for 27 days after a 50% dose reduction on day 1 and intravenous cytarabine 1000 mg/m2 per dose every 12 h for eight doses on days 8-11 (cohort A), with intravenous idarubicin (12 mg/m2 on day 8; cohort B) and dexrazoxane or intravenous azacitidine (75 mg/m2 on days 1-7; cohort C). Here, we report results for all patients treated at the RP2D, including patients treated in the expansion cohort phase (cohort A and B) and patients in cohort C added by protocol amendment (Oct 13, 2020). This final report describes the key secondary endpoint of the rates of complete response with or without haematological recovery at the RP2D. Analyses were on the intention-to-treat population. This trial was registered with ClinicalTrials.gov (NCT03194932) and is completed. FINDINGS: From July 1, 2017, to July 22, 2022, 61 patients were enrolled and 44 patients were subsequently included and treated at the RP2D (21 [48%] female, 23 [52%] male; 22 [50%] in cohort A, 15 [34%] in cohort B, and seven [16%] in cohort C). The median follow-up was 5·3 years (IQR 4·2-6·3). After 1 cycle, 25 (57% [95% CI 41-72]) patients had a complete response with or without haematological recovery; 19 were negative for measurable residual disease. Common grade 3 or 4 adverse events included febrile neutropenia (23 [52%]), gastrointestinal disorders (14[32%]]) including colitis (four [9%]), and infections (11 [25%]). There were two grade 5 adverse events due to sepsis and multiorgan failure. INTERPRETATION: Venetoclax with high-dose cytarabine is active with acceptable safety in paediatric patients with relapsed or refractory AML. These findings support ongoing research of venetoclax with high-dose cytarabine in this population, including the randomised paediatric phase 3 trial (NCT05183035). FUNDING: US National Institutes of Health (NIH), American Lebanese Syrian Associated Charities (ALSAC), AbbVie, Gateway for Cancer Research.
引用
- Daniels KP, Pounds SB, Wu H, et al. Venetoclax in combination with cytarabine with or without idarubicin or azacitidine in children, adolescents, and young adults with relapsed or refractory acute myeloid leukaemia (VENAML): a multicentre, phase 1 expansion study. Lancet Haematol. 2026. PMID: 42419338. doi:10.1016/S2352-3026(26)00136-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。